Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
487 questions in 49 reviews · Breast Cancer
current versionsNo studies 44 · 9%Ungraded 14 · 2.9%Very low 108 · 22.2%Low 128 · 26.3%Moderate 107 · 22%High 86 · 17.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Physical activity vs control Fatigue change from baseline to end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 13 studies · 1289 participants | Low |
Physical activity vs control Cardiorespiratory fitness change from baseline to end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 9 studies · 863 participants | Very low |
Physical activity vs control Emotional function/mental health at end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 26 studies · 2102 participants | Moderate |
Physical activity vs control Perceived physical function at end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 25 studies · 2129 participants | Moderate |
Physical activity vs control Anxiety at end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 7 studies · 326 participants | Very low |
Physical activity vs control Depression at end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 12 studies · 657 participants | Low |
Physical activity vs control Fatigue at end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 26 studies · 2020 participants | Moderate |
Physical activity vs control Cardiorespiratory fitness at end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 23 studies · 1265 participants | Moderate |
Physical activity vs control HRQoL change from baseline to end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 14 studies · 1459 participants | Low |
Physical activity vs control Emotional function/mental health change from baseline to end of intervention · women with breast cancer after adjuvant therapy Physical activity for women with breast cancer after adjuvant therapy (2018) · Cochrane | no estimate extracted | 15 studies · 1579 participants | Low |
Intervention NR Overall survival ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC) Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | HR 1.01 [0.92, 1.12] | 16 studies · 2531 participants | High |
Intervention NR Leukopenia** grade 3 or 4 (safety population) · women with metastatic breast cancer Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | RR 1.38 | 22 studies · 3176 participants | Moderate |
Intervention NR Progression‐free survival/time to progression (randomised participants) ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC) Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | HR 0.92 [0.84, 1.01] | 13 studies · 1745 participants | Moderate |
Intervention NR Objective tumour response rate (assessable participants) ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC) Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | RR 1.11 [1.04, 1.19] | 23 studies · 3252 participants | Low |
Intervention NR Overall survival ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | HR 0.75 [0.57, 1] | 3 studies · 391 participants | Low |
Intervention NR Progression‐free survival/time to progression (randomised participants) ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | HR 0.59 [0.49, 0.72] | 3 studies · 391 participants | Low |
Intervention NR Objective tumour response rate (assessable participants) ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC) Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | RR 1.33 [1.13, 1.56] | 5 studies · 878 participants | Low |
Intervention NR Nausea/vomiting* grade 3 or 4 (safety population) by type of platinum agent in platinum regimen · women with metastatic breast cancer Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | RR 0.77 | 7 studies · 1441 participants | Moderate |
Intervention NR Anaemia grade 3 or 4 (safety population) by type of platinum agent in platinum regimen · women with metastatic breast cancer Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | RR 1.72 | 7 studies · 1441 participants | High |
Intervention NR Hair loss grade 3 or 4 (safety population) · women with metastatic breast cancer Platinum‐containing regimens for metastatic breast cancer (2017) · Cochrane | RR 1.41 | 13 studies · 1452 participants | High |
Bisphosphonates vs placebo/observation Bone metastases · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | RR 0.86 [0.75, 0.99] | 11 studies · 15005 participants | Moderate |
Bisphosphonates vs placebo/observation Infusion‐related side effects · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | no estimate extracted | 7 studies · 7 participants | Moderate |
Bisphosphonates vs placebo/observation Bone metastases · women with advanced breast cancer without bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | RR 0.96 [0.65, 1.43] | 3 studies · 330 participants | Moderate |
Bisphosphonates vs placebo/observation Median time to a skeletal‐related event (SRE) · women with advanced breast cancer without bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | no estimate extracted | 1 study · 73 participants | Low |
Bisphosphonates vs placebo/observation Overall survival · women with advanced breast cancer without bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | RR 0.89 [0.73, 1.09] | 3 studies · 330 participants | High |
Bisphosphonates vs placebo/observation Quality of life · women with advanced breast cancer without bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | no estimate extracted | 1 study · 124 participants | Moderate |
Bisphosphonates vs placebo/observation Skeletal‐related event (SRE) · women with metastatic breast cancer with bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | RR 0.86 [0.78, 0.95] | 9 studies · 2810 participants | High |
Bisphosphonates vs placebo/observation Median time to a skeletal‐related event · women with metastatic breast cancer with bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | no estimate extracted | 9 studies · 2891 participants | High |
Bisphosphonates vs placebo/observation Overall survival · women with metastatic breast cancer with bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | RR 1.01 [0.91, 1.11] | 7 studies · 1935 participants | Moderate |
Bisphosphonates vs placebo/observation Bone pain · women with metastatic breast cancer with bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | no estimate extracted | 11 studies · 3297 participants | Moderate |
Bisphosphonates vs placebo/observation Quality of life · women with metastatic breast cancer with bone metastases Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | no estimate extracted | 5 studies · 1888 participants | Moderate |
Bisphosphonates vs placebo/observation Overall survival · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | HR 0.91 [0.83, 0.99] | 9 studies · 13949 participants | High |
Bisphosphonates vs placebo/observation Overall survival postmenopausal women · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | HR 0.77 [0.66, 0.9] | 4 studies · 6048 participants | High |
Bisphosphonates vs placebo/observation Overall survival: pre‐ or perimenopausal women · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | HR 1.03 [0.86, 1.22] | 2 studies · 3501 participants | High |
Bisphosphonates vs placebo/observation Disease‐free progression · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | HR 0.94 [0.87, 1.02] | 7 studies · 12578 participants | High |
Bisphosphonates vs placebo/observation Disease‐free progression: postmenopausal women · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | HR 0.82 [0.74, 0.91] | 7 studies · 8314 participants | High |
Bisphosphonates vs placebo/observation Disease‐free progression: pre‐ or perimenopausal women · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | HR 1.01 [0.9, 1.13] | 4 studies · 5493 participants | High |
Bisphosphonates vs placebo/observation Fracture incidence · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | RR 0.77 [0.54, 1.08] | 6 studies · 7602 participants | Moderate |
Bisphosphonates vs placebo/observation Osteonecrosis of the jaw (ONJ) · women with early breast cancer Bisphosphonates and other bone agents for breast cancer (2017) · Cochrane | no estimate extracted | 9 studies · 13242 participants | High |
No axillary surgery vs full axillary surgery All‐cause mortality · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | HR 1.06 [0.96, 1.17] | 10 studies · 3849 participants | Moderate |
Sentinel node biopsy vs full axillary surgery Paraesthesia · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | OR 0.15 [0.09, 0.23] | 2 studies · 495 participants | Low |
Sentinel node biopsy vs full axillary surgery Pain · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | OR 0.44 [0.3, 0.67] | 2 studies · 877 participants | Low |
Sentinel node biopsy vs full axillary surgery Numbness · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | OR 0.43 [0.34, 0.54] | 3 studies · 1799 participants | Moderate |
Radiotherapy alone vs full axillary surgery All‐cause mortality · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | HR 1.1 [1, 1.21] | 4 studies · 2469 participants | High |
Radiotherapy alone vs full axillary surgery Local recurrence · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | HR 0.8 [0.64, 0.99] | 4 studies · 22256 participants | High |
No axillary surgery vs full axillary surgery Locoregional recurrence · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | HR 2.35 [1.91, 2.89] | 5 studies · 20863 participants | Moderate |
No axillary surgery vs full axillary surgery Lymphoedema Increase in arm circumference · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | OR 0.31 [0.23, 0.43] | 4 studies · 1714 participants | Low |
No axillary surgery vs full axillary surgery Arm or shoulder movement impairment · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | OR 0.72 [0.49, 1.05] | 5 studies · 1495 participants | Very low |
Axillary sampling vs full axillary surgery All‐cause mortality · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | HR 0.94 [0.73, 1.21] | 3 studies · 967 participants | Low |
Axillary sampling vs full axillary surgery Local recurrence · women with operable primary breast cancer Axillary treatment for operable primary breast cancer (2017) · Cochrane | HR 1.41 [0.94, 2.12] | 3 studies · 1404 participants | Low |